Cell-based therapies for cardiac disease: a cellular therapist's perspective.
Cell-based therapies for cardiac disease: a cellular therapist's perspective.
复制标题
基于细胞的心脏病疗法：细胞治疗师的观点。
DOI：
10.1111/trf.12826
复制
发表时间：
2015-03
期刊：
影响因子：
2.9
通讯作者：
Schäfer R
中科院分区：
文献类型：
--
作者：
Young PP;Schäfer R
基于细胞的治疗是一种令人兴奋的，有前途的，正在发展的心脏疾病新疗法。基于干细胞的治疗有可能从根本上改变缺血性心脏损伤和心力衰竭的治疗，实现了几年前还无法想象的心肌再生的圣杯。最近的治疗方法涉及骨髓（BM）来源的单核细胞及其亚群，例如间充质干细胞/基质细胞（MSC）、内皮祖细胞以及脂肪组织来源的MSC、心脏组织来源的干细胞和细胞组合。使用这些细胞的临床试验已经证明细胞疗法是可行和安全的。关于输送方法，已经确定了基于导管、经内分泌和心外膜干细胞注射的安全性。然而，结果虽然可变，但表明在心力衰竭和缺血性心脏病（如急性心肌梗死）中的总体临床疗效相当有限。未来的研究将集中在确定最有效的细胞类型和/或细胞组合，最合理的适应症和最佳移植时机，以及其治疗作用的机制。我们将回顾和总结迄今为止的临床试验结果。此外，我们还讨论了心脏应用中细胞处理的挑战和操作问题。
Cell-based therapy is an exciting, promising, and a developing new treatment for cardiac diseases. Stem cell–based therapies have the potential to fundamentally transform the treatment of ischemic cardiac injury and heart failure by achieving what would have been unthinkable only a few years ago—the Holy Grail of myocardial regeneration. Recent therapeutic approaches involve bone marrow (BM)-derived mono-nuclear cells and their subsets such as mesenchymal stem/stromal cells (MSCs), endothelial progenitor cells as well as adipose tissue–derived MSCs, cardiac tissue–derived stem cells, and cell combinations. Clinical trials employing these cells have demonstrated that cellular therapy is feasible and safe. Regarding delivery methods, the safety of catheter-based, transendocardial and -epicardial stem cell injection has been established. However, the results, while variable, suggest rather modest clinical efficacy overall in both heart failure and ischemic heart disease, such as in acute myocardial infarction. Future studies will focus on determining the most efficacious cell type(s) and/or cell combinations and the most reasonable indications and optimal timing of transplantation, as well as the mechanisms underlying their therapeutic effects. We will review and summarize the clinical trial results to date. In addition, we discuss challenges and operational issues in cell processing for cardiac applications.
登录
查看更多内容
影响因子：
168.9
作者：
Makkar, Raj R.;Smith, Rachel R.;Cheng, Ke;Malliaras, Konstantinos;Thomson, Louise E. J.;Berman, Daniel;Czer, Lawrence S. C.;Marban, Linda;Mendizabal, Adam;Johnston, Peter V.;Russell, Stuart D.;Schuleri, Karl H.;Lardo, Albert C.;Gerstenblith, Gary;Marban, Eduardo
通讯作者：
Marban, Eduardo
DOI：
10.1161/atvbaha.109.198895
发表时间：
2010-06-01
影响因子：
8.7
作者：
Kumar, Arun H. S.;Caplice, Noel M.
通讯作者：
Caplice, Noel M.
影响因子：
3
作者：
Lecina, Marti;Ting, Sherwin;Oh, Steve
通讯作者：
Oh, Steve
DOI：
10.1016/s0735-1097(01)01200-1
发表时间：
2001-05-01
影响因子：
24
作者：
Fuchs, S;Baffour, R;Kornowski, R
通讯作者：
Kornowski, R
影响因子：
168.9
作者：
Janssens, S;Dubois, C;Van de Werf, F
通讯作者：
Van de Werf, F